March 10 (Reuters) – VBI Vaccines Inc said on Wednesday the Coalition for Epidemic Preparedness Innovations (CEPI) will give up to $33 million to help the company develop a vaccine candidate against the variant of the coronavirus first identified in South Africa.
The funding will support the early-stage testing of VBI-2905, which is expected to begin mid-2021, VBI said.
It will also help preclinical testing of additional vaccine candidates against other emerging variants, the drug developer added.
Norway-based CEPI, which was set up in 2017 to fight emerging epidemics, said it has so far signed 12 partnerships to develop vaccines against the coronavirus. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)
(c) Copyright Thomson Reuters 2021. Click For Restrictions – https://agency.reuters.com/en/copyright.html